• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 8, 2019

View Archived Issues

Topivert points to 'meaningful effects' amid phase IIb/III dry eye trial miss

LONDON – The multiple causes and heterogeneous patient population have confounded yet another dry eye disease study, with Topivert Pharma Ltd. reporting TOP-1630 failed to meet the primary endpoint in the THEIA-1 phase IIb/III trial. Read More

Winning the hunger game: Rhythm NDA pace well set with POMC, LEPR findings

As expected, Rhythm Pharmaceuticals Inc. rolled out positive top-line results from two pivotal, phase III trials evaluating setmelanotide, the company's melanocortin-4 receptor (MCR4R) agonist, for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities.  Read More

Glycomine completes $33M series B financing to advance glycosylation studies

With a $33 million series B round now under his belt, Glycomine Inc.'s CEO said serendipity is a large part of what brought the company to study glycosylation disorders, a rare disease that affects about 1,000 people. Read More

China's Hicin gets global rights to IDH inhibitor in $33M Nerviano deal

BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML). Read More

Myriad to seek FDA nod for CDx with Lynparza in prostate cancer

Myriad Genetics is hoping to soon add prostate cancer to the growing list of indications for use of its BRACAnalysis CDx in combination with Lynparza (olaparib), following the announcement of positive results in a subset of prostate cancer patients.  Read More

South Korea to fast track new drug approval, clinical stem cell therapy research

HONG KONG – Aiming to accelerate its biopharmaceutical R&D and marketing approvals, South Korea's Ministry of Food and Drug Safety (MFDS) and Ministry of Health and Welfare recently announced the Proposal of Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act had passed the country's National Assembly plenary session at the beginning of August and will come into force in a year's time. Read More

Big changes are coming to BioWorld! Your opinion is requested

We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More

Earnings

Intercept Pharmaceuticals Inc., of New York, posted second-quarter sales of liver disease drug Ocaliva (obeticholic acid) totaling $65.9 million, marking a growth of 53% over the prior quarter. Read More

Other news to note

Caladrius Biosciences Inc., of Basking Ridge, N.J., and Cognate Bioservices Inc., of Memphis, Tenn., signed a manufacturing agreement for the production of CLBS-14, Caladrius' CD34-positive cell therapy.  Read More

Financings

Obseva SA, of Geneva, said it closed a $75 million senior secured credit facility with Oxford Finance LLC. The nondilutive financing agreement provides funds in three tranches, with the initial $25 million available upon closing.  Read More

Regulatory front

If the Trump administration wants to move forward with the Safe Importation Action Plan it announced last week, the FDA needs to reinstate unannounced inspections of drug manufacturing facilities in other countries, Sen. Chuck Grassley (R-Iowa) said Tuesday in a letter to Acting FDA Commissioner Ned Sharpless and Health and Human Services (HHS) Secretary Alex Azar.  Read More

Appointments and advancements

Vor Biopharma Inc., of Cambridge, Mass., appointed Robert Ang president and CEO and Bill Lundberg to its board. Read More

Clinical data for Aug. 7, 2019

Read More

Regulatory actions for Aug. 7, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe